Monoamine oxidase (MAO) inhibitors were the first antidepressant drugs to be prescribed and are still used today with great success, especially in patients resistant to other antidepressants. In this study, we evaluated the MAO inhibitory properties and the potential antidepressant action of 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice. We found that 2-DMPI inhibited both MAO isoforms (K i values were 1.53 (1.3-1.8) μM and 46.67 (31.8-68.4) μM for MAO-A and MAO-B, respectively) with 30-fold higher selectivity toward MAO-A. In relation to the nature of MAO-A inhibition, 2-DMPI showed to be a mixed and reversible inhibitor. The treatment with 2-DMPI (100-1000 μmol/kg, s.c.) caused a significant decrease in immobility time in the tail suspension test (TST) without affecting locomotor activity, motor coordination or anxiety-related activities. Conversely, moclobemide (1000 μmol/kg, s.c.) caused a significant increase in immobility time in the TST, which appeared to be mediated by a nonspecific effect on motor coordination function. 2-DMPI (300 μmol/kg, s.c.) decreased serotonin turnover in the cerebral cortex, hippocampus and striatum, whereas dopamine turnover was diminished only in the striatum, and norepinephrine turnover was not changed. The antidepressant-like effect of 2-DMPI was inhibited by the pretreatment of mice with methysergide (2 mg/kg, s.c., a non-selective serotonin receptor antagonist), WAY100635 (0.1 mg/kg, s.c., a selective 5-HT 1A receptor antagonist) or haloperidol (0.05 mg/kg, i.p., a non-selective dopamine receptor antagonist). These results suggest that 2-DMPI is a prototype reversible and preferential MAO-A inhibitor with potential antidepressant activity, due to its modulatory effect on serotonergic and dopaminergic systems.
Introduction
Depression is a chronic, recurring and potentially life-threatening psychiatric illness that affects approximately 20% of the worldwide population (Berton and Nestler, 2006) . Although several different antidepressant drugs are available to treat depression, all of these compounds modulate monoamine neurotransmission, specially serotonergic and noradrenergic systems (Wong and Licinio, 2004) . However, increasing evidence from human and animal studies suggest a relationship between dopamine (DA) neurotransmission and depression (Dailly et al., 2004; Millan, 2004; Papakostas, 2006) .
Monoamine oxidase (MAO; EC 1.4.3.4) catalyses the oxidative deamination of biogenic amines, such as serotonin (5-hydroxytryptamine, 5-HT), norepinephrine (NE) and DA, and it seems to play important roles in several psychiatric and neurological disorders. MAO is a flavin adenine dinucleotide (FAD)-dependent enzyme located at the outer mitochondrial membrane of monoaminergic neurons, glia, and other cells. On the basis of pharmacological, biochemical and genetic studies, two isoforms of MAO were proposed and designated MAO-A and MAO-B (Bach et al., 1988; Johnston, 1968) . MAO-A preferentially deaminates 5-HT and is inhibited by low concentrations of clorgyline, whereas MAO-B deaminates phenylethylamine and benzylamine and is inhibited by low concentrations of selegiline. Epinephrine, NE, DA, tryptamine and tyramine are oxidized by both isoforms of the enzyme in most species (Youdim et al., 2006) .
Monoamine oxidase inhibitors (MAOIs) have been used for decades in the treatment of depression and their antidepressant properties result from selective MAO-A inhibition in the central nervous system, which could lead to increased brain levels of 5-HT, NE and DA (López-Muñoz et al., 2007; Robinson, 2002) . Moreover, Meyer et al. (2006) , using positron emission tomography, found a marked increase in brain MAO-A levels in patients with major depressive disorders compared with healthy subjects, suggesting that elevated MAO-A levels may be the primary cause of monoamine depletion in depression. In fact, MAOIs were the first antidepressant drugs described and are still used today with great success, especially in patients who are resistant to other treatments (Berton and Nestler, 2006; López-Muñoz et al., 2007; Thase et al., 1995; Wong and Licinio, 2004) . Although the first generation of irreversible and nonselective MAOIs (i.e., phenelzine and tranylcypromine) displayed antidepressant activity, they induced serious side effects, such as acute hypertensive crises, when given in combination with foods containing tyramine. These liabilities led to the search for a second generation of MAOIs (i.e., clorgyline) that exhibited an irreversible and selective profile. However, undesirable hypertensive crises persisted, limiting the use of second-generation MAOIs. Afterward, selective and reversible MAO-A inhibitors, having a much better safety profile than irreversible inhibitors, have been described (López-Muñoz et al., 2007; Robinson, 2002) .
Recently, a series of 2-substituted-2-imidazoline compounds were synthesized using a greener synthetic approach, and their ability to inhibit in vitro MAO activity was evaluated in rat brain (Sant'Anna et al., 2009 ). Potent and selective inhibitory activities toward both MAO isoforms were observed for certain compounds, including 2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole (2-DMPI). Thus, the aims of this study were to evaluate the MAO inhibitory properties of 2-DMPI in mice brain and its effects on a predictive test for antidepressant activity (the tail suspension test), as well as on monoamine metabolism and the participation of the monoaminergic system in the potential antidepressant-like action of this compound. We also investigated the effect of 2-DMPI during tests of locomotor activity, motor coordination and anxiety-related activities.
Materials and methods

Animals
Male Swiss mice (25-30 g) from our own colony were used in this study. Mice were maintained in polycarbonate cages with free access to food and water and on a 12 h alternating light-dark schedule in a temperature-controlled room (22 ± 3°C). The animals were allowed to adapt to the test environment for 2 days before testing. Mice were kept and used in accordance to the guidelines of the National Council for Control of Animal Experiments (CONCEA) and the National Institutes of Health guide for the care and use of Laboratory Animals. All experiments pertaining to this study were approved by the Ethics Committee of the Federal University of Santa Maria (process number 59/2008). For behavioral tests, drugs were administered in random order, and the behavioral measure was carried out by a blinded investigator. Each mouse was tested individually and only once. Results of mice treated with any drug were compared with those obtained for a vehicle treated (control) group.
Drugs
The synthesis of 2-DMPI was carried out by the previously reported method of condensation involving aldehydes and ethylenediamine in the presence of N-bromosuccinimide (Sant'Anna et al., 2009). The chemical structure of 2-DMPI is shown in Fig. 1A . Analysis of 1 H and 13 C Nuclear magnetic resonance spectra showed analytical and spectroscopic data in full agreement with the assigned structure. For in vivo studies, 2-DMPI and moclobemide (Aurorix®, Roche, Brazil) were dissolved in a vehicle solution (5% Tween 80, 20% polyethyleneglycol and 75% saline), and for in vitro studies, in 10% dimethyl sulfoxide (maximum final concentration of 1%). WAY100635 and methysergide (Sigma Chemical Co., St. Louis, USA), diazepam (Compaz®, Cristália, Brazil) and haloperidol (Haldol®, Janssen-Cilag, Brazil) were dissolved in saline. All other reagents were of analytical grade and were purchased from local suppliers. Injections were performed in a 10 mL/kg volume by the subcutaneous (s.c.) or intraperitoneal (i.p.) route.
Biochemical measurements
2.3.1. Determination of the kinetic parameters of MAO inhibition in vitro 2-DMPI was tested for its in vitro inhibitory potential on mice MAO-A and MAO-B activities in brain mitochondrial preparations by a fluorometric method using kynuramine as a substrate, as previously described (Matsumoto et al., 1985; Sant'Anna et al., 2009) . Briefly, assays were performed in duplicate in a final volume of 500 μL containing 0.45 mg of protein and incubated at 37°C for 30 min. Activities of the A and B isoforms were isolated pharmacologically by incorporating 250 nM selegiline (selective MAO-B inhibitor) or 250 nM clorgyline (selective MAO-A inhibitor) into the reaction mix. The reaction mixture (containing mitochondrial fractions, 2-DMPI and inhibitors) was preincubated at 37°C for 5 min, and the reaction was started by the addition of 50 μL of kynuramine (90 μM for MAO-A and 60 μM for MAO-B). Also, 2-DMPI and moclobemide were tested at a concentration range of 1 to 1000 μM, and the IC 50 and K i values for both MAO isoforms were determined.
For kinetic experiments, various concentrations of kynuramine (1-300 μM) were used, and the MAO-A activity was determined in the absence or presence of different concentrations of 2-DMPI (10, 30 or 100 μM) in order to calculate K m and V max values.
The reversibility of MAO-A inhibition was studied using the dialysis method as described by Harfenist et al. (1996) with minor modifications. Mixtures of buffer, brain mitochondrial preparations and selegiline with and without 2-DMPI (30 μM) were dialyzed at 25°C for 24 h. In the control mixture, 0.003% dimethyl sulfoxide (DMSO) was added. For each 1 mL of mixture dialyzed, 40 mL of outer buffer (16.8 mM Na 2 HPO 4 , 10.6 mM KH 2 PO 4 , 3.6 mM KCl, 1 mM dithiothreitol) was used. The outer buffer was replaced with fresh buffer at 1, 2, 4 and 6 h after the start of dialysis. Undialyzed portions of each mixture were maintained at 25°C over the same time period. Twenty-four hours after the start of dialysis, dialyzed and undialyzed mixtures were simultaneously assayed for MAO-A activity in order to evaluate the reversibility of the inhibition produced by 2-DMPI.
Monoamine neurotransmitters and metabolites levels
Mice were killed 2 h after the administration of 2-DMPI (300 μmol/kg, s.c.) or vehicle solution (10 mL/kg, s.c.). The brains were excised, and the cerebral cortex, hippocampus and striatum were immediately separated and stored at −80°C until analyzed by high-performance liquid chromatography (HPLC). The levels of the monoamines DA, 5-HT, NE and their metabolites homovanillic acid (HVA), 3,4-dihydroxyphenylacetic acid (DOPAC), 5-hydroxyindole acetic acid (5-HIAA) and 3,4-dihydroxyphenylglycol (DHPG) were estimated by high performance liquid chromatography (HPLC) with electrochemical detection, as described by Ferraz et al. (2002) .
Behavioral measurements 2.4.1. Tail suspension test (TST)
Antidepressant-like effect was measured using the tail suspension test (Steru et al., 1985) , with minor alterations (Tonello et al., 2012) . Mice were suspended by their tail using adhesive tape placed approximately 1 cm from the tip of the tail and hung approximately 30 cm above the table. The animals were suspended for a period of 6 min, and the duration of immobility was scored manually during the last 4 min interval of the test (activity in the first 2 min was discarded because animals predominantly try to escape during this period). Mice were considered immobile only when they hung passively.
For the time-course curve, mice were submitted to the TST 0.5, 1, 2, 4 or 6 h after the administration of 2-DMPI (300 μmol/kg, s.c.) or vehicle solution (10 mL/kg, s.c.). For the dose-response curve, mice were treated with 2-DMPI (30, 100, 300 or 1000 μmol/kg, s.c.; equivalent to 6, 21, 62 or 206 mg/kg, respectively) or vehicle solution 2 h before the TST. Moclobemide (30, 100, 300 or 1000 μmol/kg, s.c., 1 h before testing; equivalent to 8, 27, 81 or 269 mg/kg, respectively) was used as a positive control.
To assess the involvement of serotonergic and dopaminergic systems in the antidepressant-like effect of 2-DMPI, mice received a single injection of methysergide (2 mg/kg, s.c., a non-selective 5-HT receptor antagonist), WAY100635 (0.1 mg/kg, s.c., a selective 5-HT 1A receptor antagonist), haloperidol (0.05 mg/kg, i.p., a non-selective DA receptor antagonist) or saline (10 mL/kg) 30 min before the administration of 2-DMPI (300 μmol/kg, s.c.) or vehicle. Two hours after treatment with 2-DMPI or vehicle, the animals were submitted to the TST. All doses of antagonists used in this work were chosen according previously published data (Duarte et al., 2008; Machado et al., 2007) .
Open field test
Spontaneous locomotor activity was assessed in an open field test, as described previously (Archer, 1973) . Animals were injected with 2-DMPI (300 μmol/kg, s.c.) or vehicle 2 h before testing. Another group of mice was treated with moclobemide (300 μmol/kg, s.c.) or vehicle 1 h before testing. The number of crossings and rearings were counted in a 5 min session.
Rota-rod test
Motor coordination activity was evaluated using the rota-rod test (Dunham and Miya, 1957) with minor alterations (Godoy et al., 2004) . The apparatus consisted of a bar (3.7 cm in diameter) divided into 3 separate compartments, placed at a 25 cm height and rotating at a fixed velocity of 8 rpm. Twenty-four hours before testing, all animals were submitted to a training session until they could remain in the apparatus for 60 s without falling. On the test day, mice received a single injection of 2-DMPI (300 or 1000 μmol/kg, s.c.) or vehicle 2 h before testing. Another group of mice was treated with moclobemide (300 or 1000 μmol/kg, s.c.) or vehicle 1 h before testing. During the test session, the total number of falls during a 4 min period was observed.
Elevated plus-maze test
Anxiety-related behavior was assessed using the mouse elevated plus-maze test (Lister, 1987) . The apparatus consists of two open arms (30 × 5 cm) and two enclosed arms (30 × 5 × 15 cm) positioned 40 cm above the floor. The junction of the four arms forms a central square platform (5 × 5 cm). Mice received a single administration of 2-DMPI (300 μmol/kg, s.c.) or vehicle 2 h before testing. As a positive control, diazepam (1 mg/kg, s.c.) was administered to mice 30 min before testing (Naderi et al., 2008) 
Statistical analysis
Data were analyzed using GraphPad Prism 4.0 software. The results were expressed as means ± SEM, except for K i values, which were reported as means followed by 95% confidence intervals. Also, the number of crossings or rearings (open field test) and fall number (rota-rod test) were expressed as medians followed by their 25th and 75th percentiles. IC 50 values were calculated by nonlinear regression using sigmoidal dose-response with a variable slope equation, whereas K m (μM) and V max (nmol/min/mg protein) values were calculated by nonlinear regression using the Michaelis-Menten (Cheng and Prusoff, 1973) . Differences between groups were evaluated for significance using the unpaired t-test, one-way analysis of variance (ANOVA) followed by StudentNewman-Keuls test or two-way ANOVA followed by Bonferroni's test for parametric data. The Mann-Whitney test was used to analyze nonparametric data (number of crossings, number of rearings and fall number). Significance was considered to be when P b 0.05.
Results
Effects of 2-DMPI on MAO activity
We observed that 2-DMPI inhibited both MAO isoforms in a concentration-dependent manner with K i values of 1.5 (1.3-1.8) μM and 46.7 (31.8-68.4) μM and n H values of 0.91 ± 0.05 and 0.93 ± 0.15 for MAO-A and MAO-B, respectively (Fig. 1B) . Subsequently, kinetic experiments for MAO-A activity were carried out using different concentrations of substrate. 2-DMPI (30 μM) caused an increase in the K m value (50.2 ± 10.0 μM) and a decrease in the V max value (0.29 ± 0.02 nmol/min/mg protein) compared to K m and V max values obtained in the absence of 2-DMPI (13.6 ± 2.1 μM and 0.53 ± 0.02 nmol/min/mg protein, respectively) (Fig. 1C) . We evaluated the reversibility of the MAO-A inhibition induced by 2-DMPI using the dialysis method. It was observed that the inhibition of MAO-A activity produced by 2-DMPI was completely reversed after 24 h of dialysis compared with undialyzed activity (Fig. 1D) . We also determined the inhibitory effect of moclobemide on MAO-A and MAO-B activities. Moclobemide selectively inhibited the MAO-A isoform in a concentration-dependent manner, showing a K i value of 7.4 (6.3-8.7) μM and an n H value of 0.72 ± 0.05 ( Fig. 2A) .
Effects of 2-DMPI in the TST
Moclobemide, used as a positive control, significantly decreased the immobility time at doses 100 (35 ± 8%) and 300 (40 ± 7%) μmol/kg when administered 1 h before testing (F(4, 33) = 12.32, P b 0.0001). However, at 1000 μmol/kg, moclobemide caused a significant increase (27 ± 13%) in immobility time compared to the vehicle-treated group (Fig. 2B ). Systemic treatment with 2-DMPI (300 μmol/kg, s.c.) significantly reduced the immobility time at 2 h and 4 h after administration (F(1,73) = 10.07, P b 0.01). This effect was not found at 0.5, 1 or 6 h after treatment (data not shown). Therefore, a 2 h pretreatment was chosen to carry out the dose-response curve and the following experiments. A significant reduction in immobility time was observed at 100 (34 ± 7%), 300 (46 ± 6%) and 1000 (29 ± 6%) μmol/kg doses of 2-DMPI (F(4,50) = 8.41, P b 0.0001; Fig. 3 ).
Effects of 2-DMPI in the open field and the rota-rod tests
The treatment with 2-DMPI (300 μmol/kg, s.c., 2 h before testing) did not cause significant alterations in both crossing (Fig. 4A) and rearing ( Fig. 4B ) numbers compared with vehicle-treated mice. Moclobemide (300 μmol/kg, s.c., 1 h before testing) caused no change in the number of crossings (Fig. 4C) ; however, it significantly decreased the rearing number compared with control mice (Fig. 4D) . In addition, 2-DMPI (300 or 1000 μmol/kg, s.c., 2 h before testing; Fig. 5A or B, respectively) caused no change in motor coordination activity compared with control animals, as evaluated by the total fall number in the rota-rod test. On the other hand, moclobemide (1000 μmol/kg, s.c., 1 h before testing) caused a significant increase in the total fall number compared to vehicle-treated mice (Fig. 5D) . At a dose of 300 μmol/kg, moclobemide did not alter the motor coordination function of mice (Fig. 5C ).
Effects of 2-DMPI in the plus-maze test
As shown in Fig. 6 , 2-DMPI (300 μmol/kg, s.c., 2 h before testing) did not cause any changes in the percentage of time (Fig. 6A) or percentage of entries (Fig. 6B) into the open arms compared to vehicle-treated mice. Diazepam (1 mg/kg, s.c.), used as positive control in this test, significantly increased the percentage of time (F(2,24) = 4.31, P b 0.05; Fig. 6A ) and percentage of entries (F(2,24) = 8.54, P b 0.01; Fig. 6B ) in the open arms compared to vehicle-treated mice.
Effects of 2-DMPI on monoamine neurotransmitter levels and its metabolites
We observed that 2-DMPI (300 μmol/kg, s.c.) induced a significant increase in hippocampal (Fig. 7A), cortical (Fig. 7B ) and striatal Values are means ± SEM for each group (n = 5-9 per group). *P b 0.05 and **P b 0.01 compared with the vehicle-treated group, one-way ANOVA followed by the Student-Newman-Keuls test. Fig. 3 . Dose-response curve of subcutaneous (s.c.) 2-DMPI administration on immobility time in the TST in mice. The values are means ± SEM for each group (n = 10-14 per group). **P b 0.01 and ***P b 0.001 compared with the control group, one-way ANOVA followed by the Student-Newman-Keuls test.
( Fig. 7C ) 5-HT levels, whereas 5-HIAA levels were significantly decreased in the cerebral cortex (Fig. 7B) and striatum (Fig. 7C) . However, 5-HIAA levels were not significantly altered in hippocampus (Fig. 7A) . Furthermore, the 5-HIAA/5-HT ratio diminished in all of the brain regions examined (Fig. 8) . We also detected an increase in DA level and a decrease in DOPAC level in the striatum of 2-DMPI treated mice (Fig. 7C) . The ratios of DOPAC/DA and HVA/DA were significantly reduced only in the striatum (Fig. 8C ) Moreover, there were no alterations in NE or DHPG levels (Fig. 7) or in the DHPG/NE ratio in any of the brain regions examined (Fig. 8). 3.6. Involvement of the serotonergic and dopaminergic systems in the antidepressant-like effect of 2-DMPI Fig. 9A shows that the pretreatment of mice with the nonselective 5-HT receptor antagonist methysergide (2 mg/kg, s.c.) significantly prevented the decrease in the immobility time elicited by 2-DMPI (300 μmol/kg, s.c.). There was a significant effect of treatment x pretreatment interaction [F(1,36) = 7.46, P b 0.01]. Moreover, the pretreatment of mice with the selective 5-HT 1A receptor antagonist WAY100635 (0.1 mg/kg, s.c.) also prevented the antidepressant-like effect produced by 2-DMPI (F(1,30) = 9.60, P b 0.01 for treatment x pretreatment interaction; Fig. 9B ). In addition, the results depicted in Fig. 9C show that the pretreatment of animals with the nonselective DA receptor antagonist haloperidol (0.05 mg/kg, i.p.) prevented the effect of 2-DMPI in the TST (F(1,32) = 9.56, P b 0.01 for treatment× pretreatment interaction).
Discussion
In the present study, 2-DMPI showed inhibitory activity for both brain MAO isoforms in mice, with a 30-fold higher selectivity being . Effects of 2-DMPI (300 or 1000 μmol/kg, s.c., 2 h before testing; panels A or B, respectively), moclobemide (300 or 1000 μmol/kg, s.c., 1 h before test; panels C or D, respectively) or vehicle (10 mL/kg, s.c., 1 or 2 h before test) treatment on the fall number in the rota-rod test in mice. Values are medians (interquartile ranges) of 7-9 animals per group. **P b 0.01 compared to the respective vehicle-treated group, Mann Whitney test. Values are means ± SEM for each group (n = 9 per group). *P b 0.05 and **P b 0.01 as compared with vehicle-and 2-DMPI-treated groups, one-way ANOVA followed by Student-Newman-Keuls' test.
observed toward MAO-A than MAO-B. Our present findings are in agreement with a previous study where 2-DMPI exhibited a higher selectivity toward cerebral MAO-A than MAO-B in rats (Sant'Anna et al. 2009 ). Because 2-DMPI was preferential inhibitor for MAO-A, kinetic experiments were carried out to further explore the inhibitory effect of 2-DMPI on MAO-A activity. We found that 2-DMPI caused a significant increase in the K m value and decrease in the V max value, exhibiting a typical profile of a mixed inhibitor. In accordance with this result, moclobemide behaved as a mixed competitive/noncompetitive MAO-A inhibitor when preincubated in vitro with brain homogenates before exposure to substrate . It was also observed that MAO-A activity was completely recovered after 24 h of dialysis. Thus, 2-DMPI was shown to be a mixed, reversible and preferential MAO-A inhibitor.
Several models of antidepressant-like action have been developed and used for rapid screening of novel drugs, such as the forced swim test (FST) and the TST. Similar to the FST, the TST is based on the observation that mice, after initial escape-oriented movements, develop an immobile posture when placed in an inescapable stressful situation. The TST has been argued to be less stressful than the FST and has greater pharmacological sensitivity (Cryan et al., 2005) . In this study, 2-DMPI decreased the immobility time when administered subcutaneously 2 h before TST at 100, 300 and 1000 μmol/kg, exhibiting an antidepressant-like effect. Moclobemide also exhibited an antidepressant-like action, decreasing the immobility time at 100 and 300 μmol/kg. However, this agent significantly increased the immobility time at a dose of 1000 μmol/kg, due to a dysfunction in motor activity as observed in the rota-rod test. This result is in agreement with a previous study showing that moclobemide causes impairment in motor performance at higher doses . The efficacy of 2-DMPI and moclobemide for reducing immobility time was similar (I max values of 46 ± 6 or 40 ± 7% for the dose of 300 μmol/kg, respectively). In accordance with our results, other reversible MAOIs, including befloxatone and toloxatone, have been demonstrated to be effective in reducing the immobility time in the TST (Prakhie and Oxenkrug, 1998; Steru et al., 1987) .
Mice submitted to the TST are usually also tested in the open field test to dissociate locomotor stimulant action from the antidepressantlike effect of antidepressants (Steru et al., 1985) . 2-DMPI, at a dose that . The results are expressed as a percentage of variation versus respective controls. Each point represents the mean value ± SEM of 7-8 animals per group. Control levels (nanograms per gram of tissue): hippocampus: 5-HT, 1589 ± 51; 5-HIAA, 819 ± 38; DA, 18 ± 2; DOPAC, 123 ± 2; HVA, 137 ± 4; NE, 591 ± 34; DHPG, 104 ± 13; cerebral cortex: 5-HT, 1438 ± 49; 5-HIAA, 488 ± 26; DA, 126 ± 18; DOPAC, 169 ± 9; HVA, 191 ± 8; NE, 470 ± 28; DHPG, 171 ± 14; striatum: 5-HT, 2088 ± 89; 5-HIAA, 939 ± 63; DA, 11280 ± 1041; DOPAC, 2113 ± 168; HVA, 1104 ± 77; NE, 414 ± 37; DHPG, 174 ± 30; *P b 0.05 and **P b 0.01 compared to the respective vehicle-treated group, unpaired t-test. was effective in the TST (300 μmol/kg, s.c.), caused no alteration in locomotor activity compared with vehicle-treated mice. The effect of 2-DMPI (300 and 1000 μmol/kg, s.c.) was also evaluated in the rotarod test, and no changes in motor coordination activity were observed. These results suggest that the antidepressant-like activity of 2-DMPI in the TST was not mediated by an unspecific stimulation of locomotor activity and that this compound did not cause any dysfunction in motor performance, even at high doses.
As some antidepressants may also possess anxiolytic properties (Liu et al., 2010) , we investigated the effect of 2-DMPI on the mouse plus-maze test. Results showed that 2-DMPI did not alter the percentage of time or the percentage of entries into the open arms compared to the control, suggesting that 2-DMPI did not present anxiolytic properties. This result is in agreement with previous studies showing that acute treatment with others MAOIs, including moclobemide, phenelzine and befloxatone, had no anxiolytic effects in several animal anxiety models (Graeff et al., 1998; Griebel et al., 1997 Griebel et al., , 1998 Hascoët et al., 2000; Holmes and Rodgers, 2003) .
Monoamine neurotransmitters, such as 5-HT, NE and DA, are believed to be involved in depressive disorders and play important roles in mediating behavioral effects of antidepressant drugs (Elhwuegi, 2004; Millan, 2004) . In order to investigate if the antidepressant-like effect of 2-DMPI was due to MAO-A inhibition, we measured the ex vivo levels of monoamines and their metabolites in three brain structures (cerebral cortex, hippocampus and striatum). It has been proposed that these brain regions might mediate certain symptoms of depression, such as cognitive abnormalities and anhedonia (Berton and Nestler, 2006) . 2-DMPI, at a dose (300 μmol/kg, s.c.) and time (2 h before testing) sufficiently effective to exert an antidepressant-like effect, significantly increased 5-HT levels in the cerebral cortex and hippocampus of mouse brain. Additionally, a decrease in 5-HIAA levels was detected in the striatum and cerebral cortex. Also, there was an increase in DA levels and a decrease in DOPAC levels in the striatum of 2-DMPItreated mice. However, NE and DHPG levels were not altered in any brain region. Thus, the antidepressant-like effect of 2-DMPI in the TST appears to be mediated by 5-HT and DA neurotransmitters but not by NE.
The ratio of the major metabolite to the corresponding monoamine is commonly used as an index of monoamine turnover (Kitanaka et al., 2005 (Kitanaka et al., , 2006 Miura et al., 1996) . In this study, 2-DMPI induced a decrease in 5-HIAA/5-HT ratios in all of the brain regions examined, indicating a reduction in 5-HT turnover. DA metabolism also was diminished but only in the striatum, as indicated by the diminution in both DOPAC/DA and HVA/DA ratios. Conversely, NE turnover was not affected in the three brain areas analyzed. These results strongly indicate that 2-DMPI exerts it antidepressant-like action by decreasing 5-HT and DA turnover, and consequently, elevating the availability of these neurotransmitters in specific regions of the brain.
As only 5-HT and DA metabolism were changed by 2-DMPI treatment, we further investigated the involvement of both serotonergic and dopaminergic systems in its antidepressant-like effect in the TST. The effects of certain pharmacological antagonists of serotonergic and dopaminergic receptors were evaluated for the anti-immobility action of 2-DMPI (300 μmol/kg, s.c., 2 h before testing) in mice.
Methysergide, a non-selective 5-HT receptor antagonist, is a useful tool used to investigate the participation of the serotonergic system in behavioral responses (Duarte et al., 2008; Rodrigues et al., 2005; Zomkowski et al., 2004) . In this study, the anti-immobility effect of 2-DMPI was abolished when mice were pretreated with methysergide, thereby confirming the involvement of the serotonergic system in the antidepressant-like effect, as observed in monoamine measurement. Several studies have suggested that 5-HT 1A receptors are particularly relevant to the antidepressant responses of numerous antidepressant drugs (Blier and Ward, 2003; Elhwuegi, 2004) . Some 5-HT 1A partial agonists (such as gespirone and buspirone) have been reported to exert an antidepressant activity in numerous clinical trials (Feiger, 1996; Feiger et al., 2003; Jenkins et al., 1990; McGrath et al., 1994; Robinson et al., 1990 ). In addition, Haddjeri et al. (1998) demonstrated that various antidepressant treatments, including MAO-A inhibition, might alleviate depression by enhancing the tonic activation of forebrain postsynaptic 5-HT 1A receptors. In our study, the pretreatment of mice with the selective 5-HT 1A receptor antagonist WAY100635 was able to prevent the anti-immobility effect produced by 2-DMPI, suggesting that this receptor subtype is involved in the mechanism for the antidepressant-like action of 2-DMPI in the TST.
Dopamine is believed to play a critical role in the neurobiology of depression and in the mechanism of action of certain antidepressant drugs (Dailly et al., 2004; Dunlop and Nemeroff, 2007; Papakostas, 2006) . In addition, a dysfunction of mesolimbic and mesocortical dopaminergic pathways is primarily implicated in the melancholic and cognitive features in depression, respectively (Millan, 2004) . A number of reports have suggested that depression may be linked to abnormally low DA levels and that the severity of the disorder is inversely correlated with central nervous system DA metabolite levels (Hamner and Diamond, 1996; Roy et al., 1985) . In this study, the anti-immobility effect of 2-DMPI was prevented by the pretreatment of mice with the nonselective dopaminergic antagonist haloperidol, confirming the participation of the dopaminergic system in its antidepressant-like activity in the TST. In agreement with this result, others have shown that dopaminergic agents present antidepressant-like activity in preclinical experiments. Dhir and Kulkarni (2007) showed that the D 2 /D 3 agonist ropinirole presented antidepressant-like activity in both the TST and the FST. Furthermore, quinpirole (a D 2 -like receptor agonist) produced a significant decrease in immobility time in the rat FST, which was blocked by haloperidol (Basso et al., 2005) .
As evidence showing that antidepressants with actions on multiple neurotransmitters have therapeutic advantages over selective serotonin reuptake inhibitors (SSRIs) increases, new antidepressant agents are likely to have this property (Nash and Nutt, 2007) . Based on the pivotal role proposed for DA in depression, it has been hypothesized that a broad-spectrum antidepressant will produce a more rapid onset and/or higher efficacy than agents inhibiting the reuptake of 5-HT and/or NE (Skolnick et al., 2003) . Furthermore, it is quite possible that the treatment of major depressive disorders with agents having pro-dopaminergic activity, such as MAOIs, may result in the greater resolution of certain symptoms of depression, such as fatigue, lethargy and hypersomnia, versus treatments with predominantly serotonergic or noradrenergic activity, such as the SSRIs and tricyclic antidepressants (Papakostas, 2006) . Therefore, 2-DMPI could be a promising compound, as it inhibited brain MAO-A activity and presented antidepressant-like activity by a mechanism dependent of both serotonergic and dopaminergic systems.
Conclusion
Taken together, our results demonstrate that 2-DMPI is a new, reversible and preferential MAO-A inhibitor that exerts its antidepressant-like activity by decreasing 5-HT and DA turnover without disrupting motor performance, even at high doses. Therefore, this compound may be a prototype for the development of novel agents with potential therapeutic value for the management of depression.
